Treatment Evidence

1 Immunological Therapies: Rituximab and Cyclophosphamide

Fluge et al. 2019 — Rituximab Phase III Trial (NEGATIVE)

Full Citation:: Fluge Ø, Rekeland IG, Lien K, et al. B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Annals of Internal Medicine. 2019;170(9):585–593. DOI:: 10.7326/M18-1451 PMID:: 30934066 Trial Registration:: ClinicalTrials.gov NCT02229942 Study Design:: Phase III randomized, double-blind, placebo-controlled, multicenter trial Sample Size:: 151 patients (77 rituximab, 74 placebo)

Key Findings: This trial was NEGATIVE. Overall response rates were 35.1% in the placebo group versus 26.0% in the rituximab group (difference 9.2 percentage points [95% CI: \(-5.5\) to 23.3]; \(p=0.22\)). The treatment groups showed no differences in fatigue scores over 24 months (difference in average score 0.02 [CI: \(-0.27\) to 0.31]; \(p=0.80\)) or any secondary endpoints (SF-36, physical function, activity levels). Serious adverse events occurred in 26.0% of rituximab patients versus 18.9% of placebo patients. Notably, the placebo response rate of 35% demonstrates substantial natural fluctuation or expectation effects in ME/CFS.

Relevance: This landmark negative trial definitively refutes B-cell depletion as a therapeutic strategy for ME/CFS, contradicting earlier promising Phase II open-label studies from the same research group. The high placebo response rate (35%) has critical implications for trial design: it demonstrates that even large apparent improvements in uncontrolled studies may not represent true drug effects. The study serves as a cautionary tale about extrapolating from small early-phase trials and emphasizes the necessity of rigorous placebo-controlled validation. Rituximab should NOT be used for ME/CFS.

Certainty Assessment:

  • Quality: High (Phase III RCT, double-blind, placebo-controlled, multicenter, published in Annals of Internal Medicine)
  • Sample: n=151 (adequate for Phase III efficacy trial)
  • Replication: This was the replication—contradicted earlier positive Phase II results from same group
  • Funding: Publicly funded (Norwegian Research Council, health trusts), no industry bias
  • Limitations: Self-reported outcomes (though standard for ME/CFS); possible heterogeneity (small subset might respond but undetectable in overall analysis)

Rekeland et al. 2024 — 6-Year Follow-up

Full Citation:: Rekeland IG, Sørland K, Neteland LL, et al. Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. PLoS One. 2024;19(7):e0307484. DOI:: 10.1371/journal.pone.0307484 PMID:: 39042627 PMCID:: PMC11265720 Study Type:: Long-term observational follow-up of RituxME (Phase III RCT) and CycloME (Phase II open-label) trials

Key Findings: At 6-year follow-up, rituximab showed no sustained benefit over placebo: 27.6% of rituximab-treated patients achieved SF-36 Physical Function ≥70 compared to 20.4% of placebo patients (not statistically significant). In contrast, the open-label cyclophosphamide group showed 44.1% achieving SF-36 PF ≥70, with 17.6% reaching normal function (PF ≥90). However, the authors explicitly caution: “cyclophosphamide carries toxicity concerns and should not be used for ME/CFS patients outside clinical trials.” The placebo group data provides valuable natural history information: approximately 20% of patients improved substantially over 6 years without specific treatment, while 15% worsened significantly.

Relevance: Confirms long-term lack of benefit for rituximab. The cyclophosphamide results are intriguing but cannot be interpreted as evidence of efficacy due to absence of placebo control, open-label design, small sample (n=34 at 6 years), and potential selection bias (94% follow-up rate may favor responders). Given cyclophosphamide’s severe toxicity (cancer risk, infertility, life-threatening infections), the uncertain benefit based solely on open-label data is insufficient to justify clinical use. The findings do, however, support the hypothesis of a possible immune-mediated subgroup and warrant investigation of safer immune-modulating agents with proper placebo-controlled trials.

Certainty Assessment:

  • Rituximab data: High certainty of lack of benefit (follow-up of rigorous RCT)
  • Cyclophosphamide data: Low certainty (no placebo control, open-label, small sample, selection bias)
  • Natural history data: Moderate certainty (from placebo arm, but 24% loss to follow-up)
  • Limitations: Cyclophosphamide findings are hypothesis-generating only; different patient populations between trials complicate cross-comparison

2 H2 Receptor Antagonists: Cimetidine

Goldstein 1986 — Historical Clinical Observations

Full Citation:: Goldstein JA. Cimetidine, ranitidine, and Epstein-Barr virus infection. Annals of Internal Medicine. 1986;105(1):139. DOI:: 10.7326/0003-4819-105-1-139_2 PMID:: 3013060 Publication Type:: Letter to the editor

Key Findings: Early clinical report suggesting H2 receptor antagonists (cimetidine/ranitidine) might benefit ME/CFS patients with Epstein-Barr virus reactivation. Goldstein reported “positive results in 90% of cases of mononucleosis treated with Tagamet,” with rapid symptom resolution (within 24 hours in acute cases). Treatment approach was extended to chronic fatigue syndrome patients based on success in acute EBV infection. Proposed mechanism: H2 receptor blockade reduces suppressor T cell function, thereby enhancing cell-mediated immunity against viral infections.

Relevance: Establishes historical precedent for H2 antagonist use in CFS and provides mechanistic rationale for immunomodulation via suppressor T cell blockade. Clinical experience suggests potential responder subgroup (EBV-driven cases), with rare but dramatic responses reported ( 1–2% of patients based on subsequent clinical experience). However, evidence quality is insufficient for general recommendations—published only as brief letter without controlled data, objective outcome measures, or standardized patient selection criteria. Notable limitation: tolerance development reported with long-term use. The paper represents hypothesis-driven clinical innovation typical of 1980s CFS treatment exploration during peak interest in “chronic Epstein-Barr virus syndrome.”

Certainty Assessment:

  • Quality: Very Low (letter/case series, no controlled design, no blinding)
  • Sample: Not specified in original letter; anecdotal reports only
  • Replication: Limited; concept explored in broader immunomodulation literature but not specifically validated for ME/CFS
  • Limitations: No controlled trial, subjective outcomes, patient selection unclear, no standardized dosing protocol, published 1986 with limited methodology; concept based on 1980s understanding of “suppressor T cells” (terminology now outdated, though mechanism remains plausible with modern understanding of regulatory T cells)

Modern Context: Recent evidence suggests two distinct mechanisms may contribute to cimetidine benefit: (1) immune modulation via H2 receptor blockade (Goldstein’s proposed mechanism), and (2) pharmacokinetic enhancement of concurrent antiviral therapy (see Stuijt 2026 below). The rare dramatic responders may represent patients with active viral reactivation and either excessive regulatory T cell function or subtherapeutic antiviral drug levels.

Stuijt et al. 2026 — Pharmacokinetic Enhancement of Antivirals

Full Citation:: Stuijt R, et al. Use of cimetidine to enhance systemic acyclovir concentrations in patients with ineffective suppressive therapy for recurring herpes simplex virus infections: A novel purpose for an old drug. British Journal of Clinical Pharmacology. 2026. DOI:: 10.1002/bcp.70313 Publication Type:: Case series Year:: 2026 (most recent evidence)

Key Findings: Cimetidine increases systemic acyclovir concentrations through competitive inhibition of renal tubular secretion (OCT2/MATE1 transporters). Patients with recurrent herpes simplex virus infections who failed standard valacyclovir suppressive therapy had confirmed subtherapeutic acyclovir plasma levels. After valacyclovir dose escalation, or in some patients only after concomitant prescription of cimetidine, adequate acyclovir levels were achieved with “significant clinical improvement.” Earlier pharmacokinetic studies quantified the effect: cimetidine co-administration increases valacyclovir AUC by 73% and acyclovir AUC by 27%. The pharmacokinetic modifications did not affect tolerability of valacyclovir.

Relevance: Provides recent clinical evidence (2026) for a second mechanism of cimetidine benefit distinct from Goldstein’s immune modulation hypothesis. Pharmacokinetic enhancement may explain treatment failures in ME/CFS patients on valacyclovir for suspected viral reactivation—subtherapeutic drug levels could result from variable absorption, metabolism, or high renal clearance. Cimetidine offers cost-effective strategy to boost antiviral efficacy without dose escalation, potentially with better tolerability. However, evidence is specific to HSV; extrapolation to EBV and other herpesviruses in ME/CFS remains uncertain. Therapeutic drug monitoring would ideally guide this approach but is not widely available for acyclovir.

Certainty Assessment:

  • Pharmacokinetics: High certainty (well-established inhibition of renal secretion, quantified in controlled studies)
  • Clinical benefit in HSV: Low-Medium certainty (case series, very recent publication awaiting independent replication)
  • Application to ME/CFS: Low certainty (no ME/CFS-specific studies; mechanistic extrapolation only)
  • Limitations: Case series design (no controls, selection bias), HSV-specific evidence, therapeutic drug monitoring not widely available, optimal cimetidine dose for this indication not established, long-term safety unknown for chronic combination therapy

Clinical Integration: The combination of Goldstein’s immune modulation mechanism (1986) and Stuijt’s pharmacokinetic enhancement mechanism (2026) suggests dual potential pathways for cimetidine benefit in ME/CFS:

  • Patients on antivirals: Pharmacokinetic boost likely primary mechanism (increased drug levels)
  • Patients without antivirals: Immune modulation may be primary mechanism (enhanced cell-mediated immunity)
  • Combination therapy: Synergistic effects possible when both mechanisms operative

Simons et al. 2019 — Comprehensive Immunomodulation Review

Full Citation:: Simons FER, Rawat A, Simons KJ. Immunomodulatory properties of cimetidine: Its therapeutic potentials for treatment of immune-related diseases. International Immunopharmacology. 2019;68:8–18. DOI:: 10.1016/j.intimp.2018.12.061 PMID:: 30802678 Publication Type:: Comprehensive review article

Key Findings: Systematic review of cimetidine’s immunomodulatory properties beyond acid suppression. Cimetidine exerts powerful effects on both innate and adaptive immune systems: reduces regulatory/suppressor T cell-mediated immunosuppression, has powerful stimulatory effects on CD8+ cytotoxic T cells, enhances cell-mediated immunity markers (increased response to skin-test antigens, lymphocyte mitogen stimulation), and modulates cytokine production (affects IL-2, IL-15, IL-1\(\beta\)). H2 receptors are differentially expressed: H1R predominantly on Th1 cells, H2R predominantly on Th2 cells and regulatory T cells. H2 blockade shifts balance toward Th1/cell-mediated immunity. Therapeutic applications investigated include viral infections (herpesviruses, viral warts), vaccine adjuvant properties, and immune-mediated conditions.

Relevance: Provides mechanistic validation for Goldstein’s clinical observations with modern immunological understanding. While immunomodulatory effects are well-documented in controlled studies, clinical translation to ME/CFS remains unvalidated. The gap between mechanistic understanding and clinical evidence remains significant—most therapeutic applications lack rigorous controlled trials. Review identifies ME/CFS as potential application based on immune dysfunction hypothesis and viral reactivation, but notes absence of controlled evidence. Supports hypothesis of possible responder subgroup (patients with excessive immunosuppression, viral reactivation, T cell dysfunction), but does not provide guidance on patient selection or biomarker-based stratification.

Certainty Assessment:

  • Mechanistic Understanding: Medium-High (well-characterized immunological effects, consistent across multiple studies)
  • Clinical Translation: Weak (most applications lack controlled trials in disease populations)
  • ME/CFS Efficacy: Very Low (mentioned as potential application, no ME/CFS-specific controlled evidence)
  • Limitations: Synthesizes heterogeneous study designs; many applications based on mechanistic reasoning without clinical validation; optimal dosing for immunomodulation unclear; long-term safety for immunological indications not established

Clinical Summary and Evidence Synthesis

Overall Certainty for ME/CFS: VERY LOW (case series, historical reports, mechanistic studies; no controlled trials)

Responder Phenotype: Clinical experience suggests only  1–2% of patients experience dramatic benefit, likely representing specific subgroup with:

  • Active herpesvirus reactivation (EBV, HHV-6) as primary driver
  • Subtherapeutic antiviral drug levels (if on concurrent therapy)
  • Excessive regulatory/suppressor T cell activity
  • Possible MCAS overlap (histamine-mediated symptoms)

Dual Mechanisms: Two distinct pathways may contribute:

  • Pharmacokinetic: Increases acyclovir/valacyclovir levels (Stuijt 2026; certainty: HIGH for mechanism, LOW for ME/CFS application)
  • Immunomodulatory: Enhances cell-mediated immunity via H2 blockade (Goldstein 1986, Simons 2019; certainty: MEDIUM for mechanism, VERY LOW for ME/CFS efficacy)

Safety Considerations:

  • Drug interaction potential: Cimetidine inhibits multiple CYP450 enzymes (extensive interactions with other medications)
  • Alternative H2 antagonists: Famotidine has fewer drug interactions, may be safer for chronic use
  • Tolerance development: Effectiveness may decrease over time with continued use
  • Long-term hormonal effects: Gynecomastia, sexual dysfunction rare but documented
  • Not recommended for chronic use without physician supervision

Research Gaps:

  • No controlled trials in ME/CFS populations
  • No biomarker studies to identify responder phenotype
  • Optimal dosing and duration unclear
  • Mechanism validation needed with modern immunological methods
  • Comparison studies with other H2 antagonists (famotidine vs. cimetidine)
  • Combination protocols with antivirals need systematic evaluation

Critical Evidence Gap:

No randomized controlled trials of cimetidine in ME/CFS exist. All evidence is from case series (Goldstein 1986; Stuijt 2026), mechanistic studies in other conditions (immune modulation in cancer and EBV), and pharmacokinetic studies (Soul-Lawton 2001 drug interactions). Application to ME/CFS remains hypothesis-driven without controlled validation. The observed clinical responses in case series could reflect placebo effects, natural disease fluctuation, or benefits from concurrent interventions rather than cimetidine-specific effects.

Clinical Recommendations:

  • NOT recommended as first-line or general treatment (evidence insufficient)

  • May be considered for treatment-refractory patients with:

    • Confirmed viral reactivation (EBV, HHV-6, CMV)
    • Failed antiviral monotherapy
    • Documented T cell abnormalities

  • Requires physician supervision due to drug interaction potential

  • Consider famotidine as alternative (fewer interactions)

  • Ideally combined with therapeutic drug monitoring if on concurrent antivirals

  • Controlled trials urgently needed to validate efficacy and identify responders

3 Low-Dose Naltrexone

Polo et al. 2019 — Retrospective Observational Study

DOI:: 10.1080/21641846.2019.1692770 Published:: November 19, 2019 Study Design:: Retrospective chart review Sample Size:: 218 ME/CFS patients

Key Findings: In this large retrospective analysis, 73.9% (n=161/218) of ME/CFS patients reported subjective improvement with low-dose naltrexone (3.0–4.5 mg/day) over mean 1.7-year follow-up. Specific improvements included vigilance/alertness (51.4%), physical performance (23.9%), and cognitive function (21.1%). No severe adverse events were reported; mild transient side effects (insomnia, nausea) occurred at treatment initiation but typically resolved. The authors explicitly acknowledge the study’s limitations, concluding: “placebo-controlled studies are needed to confirm these findings.”

Relevance: This is the largest observational study of LDN in ME/CFS, suggesting potential benefit with an excellent safety profile. However, the absence of placebo control is a critical limitation. Given that the rituximab trial demonstrated 35% placebo response, the 74% response rate to LDN in an open-label setting cannot be assumed to represent true drug effect. Additional concerns include retrospective design, subjective outcomes, selection bias (which patients were prescribed LDN?), and lack of validated outcome measures. That said, LDN’s favorable safety profile, low cost (generic), and mechanistic plausibility (opioid receptor modulation, immune effects) make it a high-priority candidate for rigorous placebo-controlled RCT testing. Given the contrast with rituximab (both looked promising in early studies; rituximab failed RCT), this study should be viewed as hypothesis-generating rather than evidence of efficacy.

Certainty Assessment:

  • Safety: High certainty (large sample, long follow-up, no serious adverse events)
  • Efficacy: Low certainty (no placebo control, retrospective design, subjective outcomes)
  • Clinical Use: May be reasonable for treatment-refractory patients with informed consent about uncertain evidence
  • Research Priority: High (safe, cheap, worth rigorous RCT validation)
  • Limitations: Retrospective, no placebo control (disqualifying for efficacy claims), undefined response criteria, no standardized dosing, single geographic location (Finland)

4 Sleep Medications: Dual Orexin Receptor Antagonists

St Onge et al. 2022 — Daridorexant Phase 3 Efficacy Review

Full Citation:: St Onge E, Phillips B, Rowe C. Daridorexant: A New Dual Orexin Receptor Antagonist for Insomnia. J Pharm Technol. 2022;38(5):297–303. DOI:: 10.1177/87551225221112546 PMID:: 36035587 PMCID:: PMC9420920 Study Design:: Phase 3 clinical trial review Sample Size:: n=1,854 (Phase 3 combined)

Key Findings: Daridorexant is a dual orexin receptor antagonist (DORA) FDA-approved for insomnia in January 2022. Unlike benzodiazepines and z-drugs that enhance GABA-A receptor activity, daridorexant blocks orexin signaling to reduce wakefulness while preserving natural sleep architecture. At 50 mg: wake after sleep onset (WASO) decreased by 18.3 minutes, latency to persistent sleep (LPS) decreased by 11.7 minutes at month 3 (both \(p\)<0.0001 vs placebo). Critically, daridorexant improved daytime functioning with no residual sedation. The 25 mg dose also showed efficacy, supporting flexible dosing.

Safety Profile: Adverse events were mild (fatigue, nasopharyngitis, headache), serious events <2%, no withdrawal symptoms or rebound insomnia upon discontinuation. No tolerance development observed. Importantly, no respiratory depression (unlike GABA-A agonists), making it safer for medically complex patients.

Certainty Assessment:

  • Quality: High (Phase 3 RCTs, FDA approval, peer-reviewed)
  • Sample: n=1,854 (adequate power)
  • Replication: Multiple Phase 3 trials with consistent findings
  • Limitations: No direct ME/CFS trials (insomnia population); limited head-to-head comparison data
  • ME/CFS Applicability: High (off-label, but safety profile ideal for patients who cannot afford daytime impairment)

Kunz et al. 2022 — 52-Week Long-Term Safety

Full Citation:: Kunz D, Dauvilliers Y, Benes H, et al. Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder. CNS Drugs. 2022;37(1):93–106. DOI:: 10.1007/s40263-022-00980-8 PMID:: 36529837 PMCID:: PMC9829592 Study Design:: 52-week open-label extension study Sample Size:: n=801

Key Findings: Over 52 weeks of continuous use: treatment-emergent adverse events 35–40%, with 91.2% mild-to-moderate. No withdrawal, rebound insomnia, or tolerance development. Improved morning alertness (not residual sedation). Safe in medically complex patients: 72.1% had comorbidities, 64.8% on polypharmacy. Falls: 1.1–2.7% with no somnolence during incidents.

Relevance to ME/CFS: The long-term safety profile is critical for ME/CFS patients requiring chronic sleep support. Traditional sedatives cause tolerance (dose escalation), dependence (withdrawal syndrome), cognitive impairment, and next-day sedation—all problematic for patients already experiencing severe fatigue and cognitive dysfunction. Daridorexant avoids these issues, making it suitable for long-term use in chronic illness populations.

López-Amador 2025 — Orexin Dysfunction in ME/CFS

Full Citation:: López-Amador N. An integrative review on the orexin system and hypothalamic dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome: implications for precision medicine. Explor Neuroprot Ther. 2025;5:1004112. DOI:: 10.37349/ent.2025.1004112 Study Type:: Integrative review Sample:: 27 studies reviewed

Key Findings: Consistent evidence of reduced orexin-A levels in ME/CFS across multiple studies. Variable orexin-B responses suggest biomarker potential for subtyping. Review proposes DORAs may ameliorate both sleep AND fatigue symptoms by targeting documented hypothalamic dysfunction. No ME/CFS trials yet—recommends controlled trials as high research priority.

Clinical Synthesis: DORAs represent a mechanistically-informed treatment option for ME/CFS sleep disturbances:

  • Mechanism targets ME/CFS pathology: Orexin dysfunction documented in ME/CFS; DORAs modulate this system
  • Dual symptom targeting: May improve both sleep AND fatigue (two core symptoms)
  • Superior safety profile: No hangover, no tolerance, no withdrawal—critical for chronic use
  • Preserved cognition: No next-day cognitive impairment (unlike GABA-A agonists)
  • Evidence quality: High for general insomnia; Medium for ME/CFS application (mechanistic rationale strong, but disease-specific trials needed)

Comparison to Traditional Sleep Aids:

Issue Traditional Sedatives DORAs (Daridorexant)
Tolerance Yes (dose escalation) No (sustained efficacy)
Dependence Yes (withdrawal) No (safe discontinuation)
Rebound insomnia Yes No
Cognitive impairment Yes No
Hangover/sedation Yes No (improved alertness)
Sleep architecture Altered (↓ REM/SWS) Preserved
Fall risk Elevated Low (1–2%)

:::